IRS-4: The Potential Drug Target of IRS-4 (G8471)

Target Name: IRS4

NCBI ID: G8471

IRS4

IRS-4: The Potential Drug Target of IRS-4

IRS-4 (Interleukin-4) is a cytokine that plays a crucial role in the immune system. It is produced by the T-cells and supports the regulation of immune responses. IRS-4 has been identified as a potential drug target due to its unique biology and its potential to treat various diseases. In this article, we will discuss the biology of IRS-4, its potential drug targets, and its potential as a therapeutic agent.

Biography of IRS-4

IRS-4 is a cytokine that is expressed in various tissues and cells of the body, including the spleen, Peyer's patches, and the skin. It is a single-chain transmembrane protein that contains four extracellular loops and a variable region. IRS-4 is characterized by its ability to induce and regulate the activity of T-cells, as well as its role in the regulation of inflammation and autoimmune diseases.

Potential Drug Targets

IRS-4 has been identified as a potential drug target due to its unique biology and its potential to treat various diseases. One of the potential drug targets of IRS-4 is its role in the regulation of T-cell development and function. IRS-4 has been shown to play a role in the regulation of T-cell proliferation and differentiation, as well as its role in the regulation of T-cell costimulation.

Another potential drug target of IRS-4 is its role in the regulation of inflammation. IRS-4 has been shown to play a role in the regulation of inflammation in various tissues and organs, including the skin and the gut. It has been shown to have anti-inflammatory effects and to have the potential to treat various inflammatory diseases, such as rheumatoid arthritis and inflammatory bowel disease.

Potential Therapeutic Applications

The potential therapeutic applications of IRS-4 are vast and span across various diseases. One of the potential therapeutic applications of IRS-4 is its use as a monoclonal antibody (MAb) target for cancer treatment. IRS-4 has been shown to have anti-tumor effects in various cancer types, including breast, lung, and ovarian cancer.

Another potential therapeutic application of IRS-4 is its use as a potential vaccine. IRS-4 has been shown to have potential as a vaccine target for various diseases, including cancer, HIV, and Influenza. Its use as a vaccine could be an effective way to prevent the spread of these diseases and to treat their symptoms.

Conclusion

In conclusion, IRS-4 is a cytokine that has the potential to be a drug target due to its unique biology and its potential to treat various diseases. Its role in the regulation of T-cell development and function, as well as its role in the regulation of inflammation, makes it an attractive target for the development of new therapeutic agents. With further research, IRS-4 has the potential to become a valuable tool for the treatment of various diseases.

Protein Name: Insulin Receptor Substrate 4

Functions: Acts as an interface between multiple growth factor receptors possessing tyrosine kinase activity, such as insulin receptor, IGF1R and FGFR1, and a complex network of intracellular signaling molecules containing SH2 domains. Involved in the IGF1R mitogenic signaling pathway. Promotes the AKT1 signaling pathway and BAD phosphorylation during insulin stimulation without activation of RPS6KB1 or the inhibition of apoptosis. Interaction with GRB2 enhances insulin-stimulated mitogen-activated protein kinase activity. May be involved in nonreceptor tyrosine kinase signaling in myoblasts. Plays a pivotal role in the proliferation/differentiation of hepatoblastoma cell through EPHB2 activation upon IGF1 stimulation. May play a role in the signal transduction in response to insulin and to a lesser extent in response to IL4 and GH on mitogenesis. Plays a role in growth, reproduction and glucose homeostasis. May act as negative regulators of the IGF1 signaling pathway by suppressing the function of IRS1 and IRS2

The "IRS4 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about IRS4 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets